Intricon (IIN) 10-Q10 May 212021 Q1 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2021	Apr. 30, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	1-5005
Entity Registrant Name	INTRICON CORPORATION
Entity Incorporation, State or Country Code	PA
Entity Tax Identification Number	23-1069060
Entity Address, Address Line One	1260 Red Fox Road
Entity Address, City or Town	Arden Hills
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55112
City Area Code	651
Local Phone Number	636-9770
Title of 12(b) Security	Common stock, par value $1.00 per share
Trading Symbol	IIN
Security Exchange Name	NASDAQ
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		9,072,253
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity Central Index Key	0000088790

Consolidated Condensed Statemen

Consolidated Condensed Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Consolidated Condensed Statements Of Operations [Abstract]
Revenue, net	$ 31,768	$ 21,503
Cost of goods sold	23,558	16,931
Gross profit	8,210	4,572
Operating expenses:
Sales and marketing	1,982	1,993
General and administrative	4,052	3,416
Research and development	1,293	1,201
Other operating expenses	35
Total operating expenses	7,362	6,610
Operating income (loss)	848	(2,038)
Interest (expense) income, net	(9)	184
Other expense, net	(77)	(107)
Income (loss) before income taxes	762	(1,961)
Income tax expense	90	18
Net income (loss)	672	(1,979)
Less: Loss allocated to non-controlling interest	(42)
Net income (loss) attributable to Intricon shareholders	$ 714	$ (1,979)
Income per share of common stock:
Basic	$ 0.08	$ (0.22)
Diluted	$ 0.07	$ (0.22)
Average shares outstanding:
Basic	8,994	8,813
Diluted	9,607	8,813

Consolidated Condensed Statem_2

Consolidated Condensed Statements Of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Consolidated Condensed Statements Of Comprehensive (Loss) Income [Abstract]
Net income (loss)	$ 714	$ (1,979)
Unrealized foreign currency translation adjustment	25	13
Realized pension and postretirement obligations	12	5
Other	115
Comprehensive income (loss)	$ 866	$ (1,961)

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 11,757	$ 8,608
Restricted cash	654	672
Short-term investment securities	23,699	19,793
Accounts receivable, net of $152 and $210 of reserves, respectively	9,452	10,115
Inventories	20,336	19,513
Contract assets	8,787	9,107
Other current assets	1,956	1,466
Total current assets	76,641	69,274
Property, plant and equipment	46,480	45,661
Less: Accumulated depreciation	32,319	31,484
Net property, plant and equipment	14,161	14,177
Goodwill	13,804	13,714
Intangible assets	10,288	10,785
Operating lease right-of-use assets, net	6,115	6,701
Investment in partnerships	600	570
Long-term investment securities	2,765	5,085
Other assets, net	876	990
Total assets	125,250	121,296
Current liabilities:
Current financing leases	12	21
Current operating leases	2,108	2,156
Accounts payable	12,132	8,670
Accrued salaries, wages and commissions	3,915	3,581
Other accrued liabilities	4,297	4,235
Total current liabilities	22,464	18,663
Noncurrent operating leases	4,166	4,726
Other postretirement benefit obligations	374	385
Accrued pension liabilities	834	907
Deferred tax liabilities, net	1,028	1,018
Other long-term liabilities	4,139	4,398
Total liabilities	33,005	30,097
Commitments and contingencies (Note 11)
Shareholders' equity:
Common stock, $1.00 par value per share; 20,000 shares authorized; 8,999 and 8,951 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	8,999	8,951
Additional paid-in capital	89,926	89,702
Accumulated deficit	(6,096)	(6,810)
Accumulated other comprehensive loss	(527)	(679)
Total shareholders' equity	92,302	91,164
Non-controlling interest	(57)	35
Total equity	92,245	91,199
Total liabilities and equity	$ 125,250	$ 121,296

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Consolidated Condensed Balance Sheets [Abstract]
Accounts receivable, reserves	$ 152	$ 210
Common stock, par value	$ 1	$ 1
Common stock, shares authorized	20,000	20,000
Common stock, shares issued	8,999	8,951
Common stock, shares outstanding	8,999	8,951

Consolidated Condensed Statem_3

Consolidated Condensed Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net income (loss)	$ 672	$ (1,979)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	1,440	921
Equity in loss of partnerships	60	45
Stock-based compensation	453	376
Change in fair value of contingent consideration	35
Provision for doubtful accounts	(58)	6
Changes in operating assets and liabilities:
Accounts receivable	726	746
Inventories	(821)	(2,738)
Contract assets	320	158
Other assets	(410)	491
Accounts payable	3,491	327
Accrued expenses	206	340
Other liabilities	(249)	71
Net cash provided by (used in) operating activities	5,865	(1,236)
Cash flows from investing activities:
Purchases of property, plant and equipment	(851)	(1,678)
Payments on liabilities for acquisition of intangible assets		(91)
Purchase of investment securities	(5,412)	(76)
Proceeds from maturities of investment securities	3,752	9,850
Net cash (used in) provided by investing activities	(2,511)	8,005
Cash flows from financing activities:
Payment of financing leases	(11)	(28)
Payments on liabilities for acquisition of intangible assets	(53)
Exercise of stock options and employee stock purchase plan shares	60	68
Withholding of common stock upon vesting of restricted stock units	(241)	(198)
Net cash (used in) financing activities	(245)	(158)
Effect of exchange rate changes on cash	22	20
Net increase in cash	3,131	6,631
Cash, cash equivalents and restricted cash, beginning of period	9,280	9,162
Cash, cash equivalents and restricted cash, end of period	12,411	15,793
Non-cash investing and financing:
Acquisition of property, plant and equipment in accounts payable	$ 122	$ 187

Consolidated Condensed Statem_4

Consolidated Condensed Statements Of Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2019	$ 8,781	$ 86,770	$ (4,286)	$ (520)	$ (253)	$ 90,492
Balance, shares at Dec. 31, 2019	8,781
Exercise of stock options, net	$ 11	4				15
Exercise of stock options, net, shares	11
Withholding of common stock upon vesting of restricted stock units	$ 22	(220)				(198)
Withholding of common stock upon vesting of restricted stock units, shares	22
Shares issued under the employee stock purchase plan	$ 5	48				53
Shares issued under the employee stock purchase plan, shares	5
Stock-based compensation		376				376
Net (loss) income			(1,979)			(1,979)
Comprehensive income				18		18
Balance at Mar. 31, 2020	$ 8,819	86,978	(6,265)	(502)	(253)	88,777
Balance, shares at Mar. 31, 2020	8,819
Balance at Dec. 31, 2020	$ 8,951	89,702	(6,810)	(679)	35	91,199
Balance, shares at Dec. 31, 2020	8,951
Exercise of stock options, net	$ 22	(15)				$ 7
Exercise of stock options, net, shares	22					84
Withholding of common stock upon vesting of restricted stock units	$ 24	(265)				$ (241)
Withholding of common stock upon vesting of restricted stock units, shares	24
Shares issued under the employee stock purchase plan	$ 2	51				53
Shares issued under the employee stock purchase plan, shares	2
Stock-based compensation		453				453
Net (loss) income			714		(42)	672
Comprehensive income				152	(50)	102
Balance at Mar. 31, 2021	$ 8,999	$ 89,926	$ (6,096)	$ (527)	$ (57)	$ 92,245
Balance, shares at Mar. 31, 2021	8,999

Management's Statement

Management's Statement	3 Months Ended
Management's Statement	Mar. 31, 2021
Management's Statement [Abstract]
Management's Statement	1. Management’s Statement Intricon Corporation (together with its subsidiaries referred herein as the “Company”, or “Intricon”, “we”, “us” or “our”) is an international company and joint development manufacturer (“JDM”) of micromedical components, sub-assemblies and final devices. The Company serves as a JDM partner to leading medical device original equipment manufacturers (“OEMs”) by designing, developing, engineering, manufacturing, packaging and distributing micromedical products for high growth markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. Our mission is to improve, extend and save lives by advancing innovative micromedical technologies through joint development and manufacturing partnerships with industry leading medical device companies. Basis of Presentation The interim consolidated condensed financial statements of the Company presented herein have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the periods presented. The interim consolidated condensed financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity. During the three months ended March 31, 2021, the Company operated under one operating segment. This is consistent with disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These consolidated condensed financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2020, included in the Company's Annual Report on Form 10-K. Use of Estimates The Company makes estimates and assumptions relating to the reporting of assets and liabilities, the recording of reported amounts of revenues and expenses and the disclosure of contingent assets and liabilities to prepare these consolidated condensed financial statements. Actual results could differ from those estimates. Considerable management judgment is necessary in estimating future cash flows and other factors affecting the valuation of goodwill and intangible assets, including the operating and macroeconomic factors that may affect them. The Company uses historical financial information, internal plans and projections and industry information in making such estimates. Summary of Significant Accounting Policies The Company’s significant accounting policies are detailed in “Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The Company follows these policies in preparation of the consolidated condensed financial statements.

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
New Accounting Pronouncements	Mar. 31, 2021
New Accounting Pronouncements [Abstract]
New Accounting Pronouncements	2. New Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses Topic 326, which requires certain financial assets to be measured at amortized cost net of an allowance for estimated credit losses, such that the net receivable represents the present value of expected cash collection. In addition, this standard update requires that certain financial assets be measured at amortized cost reflecting an allowance for estimated credit losses expected to occur over the life of the assets. The estimate of credit losses must be based on all relevant information including historical information, current conditions, and reasonable and supportable forecasts that affect the collectability of the amounts. Topic 326 is effective for interim and annual periods beginning January 1, 2022 for smaller reporting companies. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows.

Revenue Recognition

Revenue Recognition	3 Months Ended
Revenue Recognition	Mar. 31, 2021
Revenue Recognition [Abstract]
Revenue Recognition	3. Revenue Recognition Revenue is measured based on consideration specified in the contract with a customer. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. For contractual arrangements in which an enforceable right exists, control of these units is deemed to transfer to the customer over time during the manufacturing process. Consequently, the transaction price is recognized as revenue over time. The transaction price for contractual arrangements without an enforceable right to payment including a reasonable margin is recognized as revenue at a point in time. The Company’s revenue recognition policy is further detailed in “Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The following tables set forth, for the periods indicated, timing of revenue recognition by market: Timing of revenue recognition for the three months ended March 31, 2021: Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 18,364 $ 18,364 Interventional Catheters 3,802 - 3,802 Other Medical 1,590 1,368 2,958 Value Based DTEC 937 - 937 Value Based ITEC 1,301 - 1,301 Legacy OEM 3,421 - 3,421 Professional Audio Communications 985 - 985 Total Revenue, net $ 12,036 $ 19,732 $ 31,768 Timing of revenue recognition for the three months ended March 31, 2020: Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 13,530 $ 13,530 Interventional Catheters - - - Other Medical 1,820 1,008 2,828 Value Based DTEC 1,173 - 1,173 Value Based ITEC 744 - 744 Legacy OEM 1,964 - 1,964 Professional Audio Communications 1,264 - 1,264 Total Revenue, net $ 6,965 $ 14,538 $ 21,503 During the quarter ended March 31, 2020, we recorded a cumulative adjustment of $ 1,200 to reduce revenue within our other medical market to correct an error related to prior periods as a result of our determination that a portion of our sales being recognized over time needed to be recognized at a point in time. The adjustment included a reduction of the related cost of goods sold of $ 800 and related impacts to reduce the contract asset and an increase to inventory. The adjustment was not material to our consolidated condensed financial statements for any quarterly or annual period. Net revenue by geography is allocated based on shipment and set forth below: Three Months Ended Net Revenue by Geography March 31, 2021 March 31, 2020 United States $ 23,701 $ 17,788 Europe 1,264 1,187 Asia 3,468 2,200 All other countries 3,335 328 Consolidated $ 31,768 $ 21,503 Geographic net revenue is allocated based on the shipment location of the Company’s direct OEM customer. For the three months ended March 31, 2021, and 2020, one customer accounted for 68 % and 63 %, respectively, of the Company’s consolidated net revenue. Two customers combined accounted for 60 % and 69 % of the Company’s consolidated accounts receivable at March 31, 2021 and December 31, 2020, respectively. Two customers accounted for the Company’s consolidated contract assets at March 31, 2021 and December 31, 2020, respectively.

Income (Loss) Per Share

Income (Loss) Per Share	3 Months Ended
Income (Loss) Per Share	Mar. 31, 2021
Income (Loss) Per Share [Abstract]
Income (Loss) Per Share	4. Income (Loss) Per Share The following table presents a reconciliation between basic and diluted net income per share: Three Months Ended March 31, 2021 March 31, 2020 Numerator: Net income (loss) $ 672 $ ( 1,979 ) Less: Loss allocated to non-controlling interest ( 42 ) - Net income (loss) attributable to Intricon shareholders $ 714 $ ( 1,979 ) Denominator: Basic – weighted shares outstanding 8,994 8,813 Weighted shares assumed upon exercise of stock awards 613 - Diluted – weighted shares outstanding 9,607 8,813 Basic income (loss) per share attributable to Intricon shareholders: $ 0.08 $ ( 0.22 ) Diluted income (loss) per share attributable to Intricon shareholders: $ 0.07 $ ( 0.22 ) Net income per common share was based on the weighted average number of common shares outstanding during the periods when computing basic net income per share. Stock options are dilutive when the average market price of Company stock exceeds the exercise price of the potentially dilutive options. When dilutive, stock options are included as equivalents using the treasury stock method when computing diluted net income per share. Unvested shares represented by RSUs are also included in the dilution calculation, net of assumed proceeds and equivalent share repurchases. For the three months ended March 31, 2020, weighted average options and RSU’s outstanding of 893 were excluded from the dilutive calculation as their effect would have been antidilutive based on losses in the period. No options or RSUs were excluded from the dilutive calculation for the three months ended March 31, 2021.

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2021
Income Taxes [Abstract]
Income Taxes	5. Income Taxes Income tax expense for the three months ended March 31, 2021 was $ 90 compared to $ 18 for the same period in 2020. The expense was largely due to our foreign operations. The Company has net operating loss carryforwards for U.S. federal income tax purposes. The Company has recorded a full valuation allowance against US deferred tax assets as of March 31, 2021. The following was the income (loss) before income taxes for each jurisdiction in which the Company has operations for the period: Three Months Ended March 31, 2021 March 31, 2020 United States $ 585 $ ( 1,842 ) Singapore 138 ( 153 ) Indonesia 21 18 Germany 18 16 Income (loss) before income taxes $ 762 $ ( 1,961 ) CARES Act On March 27, 2020, in response to the impact of the COVID-19 pandemic in the U.S. and across the Globe, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted, which contained certain tax benefits that were not material to the Company.

Business Combination

Business Combination	3 Months Ended
Business Combination	Mar. 31, 2021
Business Combination [Abstract]
Business Combination	6. Business Combination Emerald Medical Services and Emerald Extrusion Services On May 18, 2020 , Intricon Pte. Ltd. (“Buyer”), a wholly-owned subsidiary of the Company, acquired all of the outstanding shares of Emerald Medical Services Pte., Ltd., a Singapore company (“EMS”) for a total purchase price of $ 11,815 . EMS, based in Singapore, is a provider of joint development medical device manufacturing services for complex catheter applications. In addition, the Company has a 54 % ownership interest in Emerald Extrusion Services LLC. (“EES), based in California. Based on this controlling financial interest, the Company has consolidated this entity. The remaining ownership is accounted for as a non-controlling interest and reported as part of equity in the consolidated condensed balance sheets. We accounted for the acquisition in accordance with ASC 805, Business Combinations, with identifiable assets acquired and liabilities assumed recorded at their estimated fair value on the acquisition date. The Company has up to one year from the acquisition date to finalize the purchase price allocation. During the period ended March 31, 2021, the Company recorded certain adjustments related to changes in valuation estimates of accounts receivable, inventory and deferred taxes as well as changes to the non-controlling interest balance. These purchase accounting adjustments resulted in a $ 90 increase to Goodwill during the 2021 first quarter. The Company expects the final purchase price allocation to be determined in May 2021. The estimated purchase price allocation of the fair value of the assets acquired and liabilities assumed as of March 31, 2021 is included in the table below. Current assets $ 3,161 Property, plant and equipment 360 Intangible assets 6,400 Goodwill 4,253 Noncurrent assets 169 Current liabilities ( 1,105 ) Noncurrent liabilities ( 1,423 ) Total consideration paid $ 11,815 A portion of the purchase price is in the form of a contingent consideration liability calculated using a scenario-based method utilizing various level 3 inputs including revenue volatility, weighted average cost of capital and discount rate percentages. Level 3 is a fair value measure in which there are no observable inputs used to value an asset or liability and the fair value is determined based on modeling and the use of management estimates and assumptions. The key valuation assumptions included forecasts of future revenues and the selection of the discount rate. The liability for contingent consideration is subject to fair value adjustments each reporting period that will be recognized through the consolidated condensed statement of operations within other operating expenses. Quantitative information about Level 3 inputs for fair value measurement of the contingent consideration liability are detailed in “Note 2: Business Combination” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. There have be no significant changes to these inputs as of March 31, 2021. Significant increases or decreases in these inputs in isolation could result in a significant impact on the fair value measurement. The reconciliation of the contingent consideration liability measured and carried at fair value on a recurring basis is as follows: Carrying amount at December 31, 2020 $ 3,574 Change in fair value 35 Carrying amount at March 31, 2021 $ 3,609 Our consolidated condensed statements of operations for the three months ended March 31, 2021 include revenues of $ 3,802 and net income of $ 249 , respectively, attributable to the acquiree. See Note 2 of our Notes to the Consolidated Financial Statements in our 2020 Annual Report on Form 10-K for more details.

Selected Balance Sheet Data

Selected Balance Sheet Data	3 Months Ended
Selected Balance Sheet Data	Mar. 31, 2021
Selected Balance Sheet Data [Abstract]
Selected Balance Sheet Data	7. Selected Balance Sheet Data Inventories: Inventories consisted of the following at: Raw materials Work-in process Finished products and components Total March 31, 2021 Domestic $ 12,256 $ 1,191 $ 2,138 $ 15,585 Foreign 3,396 1,239 116 4,751 Total $ 15,652 $ 2,430 $ 2,254 $ 20,336 December 31, 2020 Domestic $ 11,371 $ 1,499 $ 2,149 $ 15,019 Foreign 3,393 968 133 4,494 Total $ 14,764 $ 2,467 $ 2,282 $ 19,513 Property, Plant and Equipment Geographic Information: The geographical distribution of long-lived assets, consisting of property, plant and equipment is set forth below: March 31, December 31, 2021 2020 United States $ 12,537 $ 12,539 Singapore 1,454 1,460 Other 170 178 Consolidated $ 14,161 $ 14,177 Long-lived assets consist of property, plant and equipment. Excluded from long-lived assets are investments in partnerships, patents, goodwill, intangible assets, operating lease right-of-use (ROU) assets and certain other assets. The Company capitalizes long-lived assets pertaining to the production of specialized parts. These assets are periodically reviewed to ensure the net realizable value from the estimated future production based on forecasted cash flows exceeds the carrying value of the assets. Goodwill: During the period ended March 31, 2021, the Company recorded certain purchase accounting adjustments for the EMS business combination resulting in an adjustment to goodwill. The changes to the carrying amount of goodwill for the periods presented are as follows: Carrying amount at December 31, 2020 $ 13,714 Purchase accounting adjustment 90 Carrying amount at March 31, 2021 $ 13,804 Intangible Assets: Definite- lived intangible assets consisted of the following at: March 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer list $ 6,400 $ ( 667 ) $ 5,733 Technology intangibles 6,725 ( 2,170 ) 4,555 Total $ 13,125 $ ( 2,837 ) $ 10,288 December 31, 2020 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer list $ 6,400 $ ( 467 ) $ 5,933 Technology intangibles 6,725 ( 1,873 ) 4,852 Total $ 13,125 $ ( 2,340 ) $ 10,785 The customer list was established as a part of purchase accounting related to our Emerald acquisition; see Note 6. The estimated useful life is eight years . The technology intangibles provide the Company with wireless and self-fitting hearing aid technology and are being amortized based on an estimated useful life between five and seven years . Investment in Partnerships: Investment in partnerships consisted of the following: March 31, December 31, 2021 2020 Investment in Signison $ 358 $ 418 Other 242 152 Total $ 600 $ 570 The Company has a 50 % ownership interest in Signison, a German based Company specializing in hearing health services. This is accounted for in the Company’s consolidated condensed financial statements using the equity method for all periods presented. Other Accrued Liabilities: Other accrued liabilities consisted of the following at: March 31, 2021 December 31, 2020 Pension and postretirement benefit obligations $ 188 $ 188 Deferred revenue 224 184 Current technology intangible liability 996 1,006 Current earn-out contingent consideration liability 1,060 1,090 Customer funded projects 776 759 Other 1,053 1,008 Total $ 4,297 $ 4,235 The technology intangible liability, reflected above, relates to amounts owed in relation to the Company’s wireless and self-fitting hearing aid technologies. The earn-out liability is contingent on certain future events and is measured at fair value based on various level 3 inputs and assumptions including forecasts, probabilities of payment and discount rates. Amounts are classified as current if expected to be paid within the next twelve months. The liability for contingent consideration is subject to fair value adjustments each reporting period that will be recognized through the Consolidated Condensed Statement of Operations. See Note 6. Other Long-Term Liabilities: Other long-term liabilities consisted of the following at: March 31, December 31, 2021 2020 Noncurrent technology intangible liability $ 710 $ 1,039 Noncurrent earn-out contingent consideration liability 2,549 2,484 Other 880 875 Total $ 4,139 $ 4,398 ` As of March 31, 2021, the Company had no debt under its existing credit facilities and was in compliance with all applicable covenants.

Investment Securities

Investment Securities	3 Months Ended
Investment Securities	Mar. 31, 2021
Investment Securities [Abstract]
Investment Securities	8. Investment Securities The Company invests in commercial paper, corporate notes and bonds with original maturities of less than two years . The Company classifies these investments as held to maturity based on our intent and ability to hold these investments until maturity. As a result, these investments are recorded at amortized cost, which approximates fair value, using level 2 inputs. The maturity dates of our investments as of March 31, 2020 are as follows: Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 10,140 $ - $ 10,140 Corporate Notes and Bonds 13,559 2,765 16,324 Total Investments $ 23,699 $ 2,765 $ 26,464 The maturity dates of our investments as of December 31, 2020 are as follows: Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 7,490 $ - $ 7,490 Corporate Notes and Bonds 12,303 5,085 17,388 Total Investments $ 19,793 $ 5,085 $ 24,878 The Company also maintains excess funds within level 1 money market accounts included within cash and cash equivalents. Cash available in our money market accounts at March 31, 2021 and December 31, 2020 was $ 6,181 and $ 6,697 , respectively.

Leases

Leases	3 Months Ended
Leases	Mar. 31, 2021
Leases [Abstract]
Leases	9. Leases The Company’s leases pertain primarily to engineering, manufacturing, sales and administrative facilities, with an initial term of one year or more. The Company has three leased facilities in Minnesota, two that expire in 2022 and one that expires in 2023, one leased facility in Illinois that expires in 2022, one leased facility in California that expires in 2022, one leased facility in Singapore that expires in 2025, one leased facility in Indonesia that expires in 2024, and one leased facility in Germany that expires in 2022. Certain foreign leases allow for variable lease payments that depend on an index or a market rate adjustment for the respective country and are adjusted on an annual basis. The adjustment is recognized as incurred in the consolidated condensed statement of operations. The facility leases include options to extend for terms ranging from one year to five years . Lease options that the Company is reasonably certain to execute are included in the determination of the ROU asset and lease liability. Our Indonesia lease includes embedded forward starting leases that will begin in 2022 and 2024 for additional square footage, which will result in the recognition of an additional ROU asset and lease liability in those periods of approximately $ 103 and $ 72 , respectively. The Company also leases equipment that include bargain purchase options at termination. These leases have been classified as finance leases. Operating cash flows for the year ended March 31, 2021, and 2020 from operating leases were $ 609 and $ 507 , respectively. Financing lease assets are classified as property, plant and equipment within the consolidated condensed balance sheet. Discount rates are determined based on 5 -year term incremental borrowing rates at inception of the lease. The following table summarizes the weighted-average lease term and discount rates: Weighted-Average Lease Term (Years) March 31, 2021 December 31, 2020 Finance leases 0.8 0.8 Operating leases 3.6 3.8 Weighted-Average Discount Rate March 31, 2021 December 31, 2020 Finance leases 5.56 % 5.56 % Operating leases 5.06 % 5.06 % The following tables summarizes lease costs by type: March 31, 2021 March 31, 2020 Lease cost Finance lease cost: Amortization of right-of-use assets $ 10 $ 26 Interest on lease liabilities 1 2 Operating lease cost 582 481 Variable lease cost 120 151 Total lease cost $ 713 $ 660 Maturities of lease liabilities are as follows as of March 31, 2021: Operating Leases Financing Leases Total 2021 $ 2,108 $ 12 $ 2,120 2022 1,938 3 1,941 2023 1,338 - 1,338 2024 1,017 - 1,017 2025 and thereafter 471 - 471 Total lease payments 6,872 15 6,887 Less: Interest ( 598 ) ( 3 ) ( 601 ) Present value of lease liabilities $ 6,274 $ 12 6,286

Shareholders' Equity And Stock-

Shareholders' Equity And Stock-Based Compensation	3 Months Ended
Shareholders' Equity And Stock-Based Compensation	Mar. 31, 2021
Shareholders' Equity And Stock-Based Compensation [Abstract]
Shareholders' Equity And Stock-Based Compensation	10. Shareholders’ Equity and Stock-based Compensation The Company has a 2006 Equity Incentive Plan and an Amended and Restated 2015 Equity Incentive Plan. The 2015 plan, which was approved by the shareholders on April 24, 2015, replaced the 2006 plan. New grants may not be made under the 2006 plan; however certain option grants under the 2006 plan remain exercisable as of March 31, 2021 . Under the 2015 Plan, the Company may grant stock options, stock awards, stock appreciation rights, restricted stock units (“RSUs”), performance restricted stock units (“PRSUs”) and other equity-based awards. Under all awards, the terms are fixed on the grant date. The 2015 plan was amended and restated in 2020 to reflect certain corporate governance changes and amended in 2021 to increase the number of shares of common stock that could be awarded under the 2015 plan by 500 shares, subject to shareholder approval, which was obtained on May 4, 2021. For the three months ended March 31, 2021, the Company granted a total of 73 RSUs at a weighted average closing price on the date of grant of $ 20.80 . The RSUs vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant at which time common stock is issued with respect to vested units. The Company has also granted stock options under the plans. For the three months ended March 31, 2021, and 2020, the Company did no t grant any options. Options granted under the plans generally vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant and have a maximum term of 10 years. During the three months ended March 31, 2021, 7 options were forfeited in order to cover the exercise price of the options. Stock award activity as of and during the three months ended March 31, 2021 was as follows: Outstanding Awards Stock Options RSUs Total Stock Option Weighted-Average Exercise Price (a) Aggregate Intrinsic Value Outstanding at December 31, 2020 690 217 907 $ 6.51 Awards granted - 73 73 - Awards exercised or released ( 31 ) ( 53 ) ( 84 ) 5.26 Outstanding at March 31, 2021 659 237 896 $ 6.57 $ 19,045 Exercisable at March 31, 2021 659 659 $ 6.57 $ 12,572 Available for future grant at December 31, 2020 73 Available for future grant at March 31, 2021 (b) 20 (a) The weighted average exercise price calculation does not include outstanding RSUs (b) Does not include an additional 500 shares approved by shareholders on May 4, 2021 The number of shares available for future grants at March 31, 2021 does not include a total of up to 297 shares subject to options outstanding under the 2006 Equity Incentive Plan, which will become available for grant under the 2015 Equity Incentive Plan as outstanding options under the 2006 Equity Incentive Plan expire, terminate, are cancelled or forfeited or are withheld in a net exercise of such options. The Company recorded $ 453 of non-cash stock compensation expense for the three months ended March 31, 2021 compared to $ 376 for the same periods in 2020. As of March 31, 2021, there was $ 3,012 of total unrecognized compensation costs related to non-vested stock option and RSU awards that are expected to be recognized over a weighted-average period of 2.33 years. The total intrinsic value of options exercised during the three months ended March 31, 2021 was $ 486 . The Company also has an Employee Stock Purchase Plan (the “Purchase Plan”). The Purchase Plan, as amended, through March 31, 2021, provides that a maximum of 300 shares may be sold under the Purchase Plan. There were 2 and 5 shares purchased under the plan for the three months ended March 31, 2021 and 2020, respectively.

Legal Proceedings

Legal Proceedings	3 Months Ended
Legal Proceedings	Mar. 31, 2021
Legal Proceedings [Abstract]
Legal Proceedings	12. Legal Proceedings Asbestos Litigation The Company is a defendant along with a number of other parties in lawsuits alleging that plaintiffs have or may have contracted asbestos-related diseases as a result of exposure to asbestos products or equipment containing asbestos sold by one or more named defendants. These lawsuits relate to the discontinued heat technologies segment which was sold in March 2005. Due to the non-informative nature of the complaints, the Company does not know whether any of the complaints state valid claims against the Company. Certain insurance carriers have informed the Company that the primary policies for the period August 1, 1970-1978 have been exhausted and that the carriers will no longer provide defense and insurance coverage under those policies. However, the Company has other primary and excess insurance policies that the Company believes afford coverage for later years. Some of these other primary insurers have accepted defense and insurance coverage for these suits, and some of them have either ignored the Company’s tender of defense of these cases, or have denied coverage, or have accepted the tenders but asserted a reservation of rights and/or advised the Company that they need to investigate further. Because settlement payments are applied to all years a litigant was deemed to have been exposed to asbestos, the Company believes that it will have funds available for defense and insurance coverage under the non-exhausted primary and excess insurance policies. However, unlike the older policies, the more recent policies have deductible amounts for defense and settlements costs that the Company will be required to pay; accordingly, the Company expects that its litigation costs will increase in the future. Further, many of the policies covering later years (approximately 1984 and thereafter) have exclusions for any asbestos products or operations, and thus do not provide insurance coverage for asbestos-related lawsuits. The Company does not believe that the asserted exhaustion of some of the primary insurance coverage for the 1970-1978 period will have a material adverse effect on its financial condition, liquidity, or results of operations. Management believes that the number of insurance carriers involved in the defense of the suits, and the significant number of policy years and policy limits under which these insurance carriers are insuring the Company, make the ultimate disposition of these lawsuits not material to the Company's consolidated financial position or results of operations. As of March 31, 2021, we recorded $ 129 and $ 721 within other accrued liabilities and other long-term liabilities, respectively, within our consolidated condensed balance sheet for estimated future claims. An insurance receivable of $ 129 and $ 721 was recorded within other current assets and other assets, net, respectively, within our consolidated condensed balance sheet as of March 31, 2021 for estimated insurance recoveries. TCPA Litigation On October 9, 2019, plaintiff Mark Hoffman (“Hoffman”) filed a putative class action lawsuit against defendant Hearing Help Express, Inc. (“HHE”), a subsidiary of the Company, in the Federal District Court for the Western District of Washington based on specific provisions of the federal Telephone Consumer Protection Act (“TCPA”). HHE’s investigation revealed third-party lead generator Triangular Media Corp. (“Triangular”) provided Hoffman’s information to HHE only after he participated in Triangular’s interactive telephonic screening process. Hoffman claims he did not provide the requisite prior express written consent for autodialed telemarketing calls regarding hearing aids to be placed to his cellphone. He also claims he did not provide the requisite permission for telemarketing calls to his number registered on the Do-Not-Call (“DNC”) registry. Since the initial complaint was filed, Hoffman has amended his complaint several times to add additional parties, including Triangular, Triangular’s alleged owner, an alleged entity related to Triangular called LeadCreations.Com, LLC, Intricon, Inc., and Intricon Corporation. With respect to HHE, Hoffman seeks to certify a class of certain automated outbound telemarketing calls HHE allegedly made without prior consent, or to those numbers on the DNC registry, in the last four years. Hoffman also seeks to hold the Company vicariously liable for all of the calls HHE made without prior consent. The potential exposure under the TCPA is $ 500 per call, or $ 1,500 per call if the violation is deemed willful or knowing. The parties were engaged in discovery. However, the case was stayed pending the United States Supreme Court’s ruling in another TCPA case – Duguid v. Facebook, No. 19-51 (argued Dec. 8, 2020) given the impact the Duguid opinion could have on this case. A ruling by the United States Supreme Court was issued on April 1, 2021 in favor of Facebook. Following the ruling, the parties agreed to continue the stay of the case and attend a private mediation to see if a resolution can be reached. Mediation is scheduled for May 24, 2021. The Company believes that HHE has strong legal and factual defenses in this proceeding. HHE and the Company intend to continue defending themselves vigorously in the pending lawsuit. While the Company is unable to predict the outcome of this proceeding, the Company believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's consolidated financial position, liquidity or results of operations. Other Litigation Matters The Company is also involved from time to time in other lawsuits arising in the normal course of business. While it is not possible to predict with certainty the outcome of these matters, management is of the opinion that the disposition of these lawsuits and claims will not materially affect the Company’s consolidated financial position, liquidity, or results of operations.

Management's Statement (Policy)

Management's Statement (Policy)	3 Months Ended
Management's Statement (Policy)	Mar. 31, 2021
Management's Statement [Abstract]
Basis Of Presentation	Basis of Presentation The interim consolidated condensed financial statements of the Company presented herein have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the periods presented. The interim consolidated condensed financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity. During the three months ended March 31, 2021, the Company operated under one operating segment. This is consistent with disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These consolidated condensed financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2020, included in the Company's Annual Report on Form 10-K.
Use Of Estimates	Use of Estimates The Company makes estimates and assumptions relating to the reporting of assets and liabilities, the recording of reported amounts of revenues and expenses and the disclosure of contingent assets and liabilities to prepare these consolidated condensed financial statements. Actual results could differ from those estimates. Considerable management judgment is necessary in estimating future cash flows and other factors affecting the valuation of goodwill and intangible assets, including the operating and macroeconomic factors that may affect them. The Company uses historical financial information, internal plans and projections and industry information in making such estimates.

New Accounting Pronouncements (

New Accounting Pronouncements (Policy)	3 Months Ended
New Accounting Pronouncements (Policy)	Mar. 31, 2021
New Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses Topic 326, which requires certain financial assets to be measured at amortized cost net of an allowance for estimated credit losses, such that the net receivable represents the present value of expected cash collection. In addition, this standard update requires that certain financial assets be measured at amortized cost reflecting an allowance for estimated credit losses expected to occur over the life of the assets. The estimate of credit losses must be based on all relevant information including historical information, current conditions, and reasonable and supportable forecasts that affect the collectability of the amounts. Topic 326 is effective for interim and annual periods beginning January 1, 2022 for smaller reporting companies. This standard update is not expected to have a material impact on our financial position, results of operations and cash flows.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
Revenue Recognition (Tables)	Mar. 31, 2021
Revenue Recognition [Abstract]
Timing Of Revenue Recognition	Timing of revenue recognition for the three months ended March 31, 2021: Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 18,364 $ 18,364 Interventional Catheters 3,802 - 3,802 Other Medical 1,590 1,368 2,958 Value Based DTEC 937 - 937 Value Based ITEC 1,301 - 1,301 Legacy OEM 3,421 - 3,421 Professional Audio Communications 985 - 985 Total Revenue, net $ 12,036 $ 19,732 $ 31,768 Timing of revenue recognition for the three months ended March 31, 2020: Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 13,530 $ 13,530 Interventional Catheters - - - Other Medical 1,820 1,008 2,828 Value Based DTEC 1,173 - 1,173 Value Based ITEC 744 - 744 Legacy OEM 1,964 - 1,964 Professional Audio Communications 1,264 - 1,264 Total Revenue, net $ 6,965 $ 14,538 $ 21,503
Net Revenue By Geography	Three Months Ended Net Revenue by Geography March 31, 2021 March 31, 2020 United States $ 23,701 $ 17,788 Europe 1,264 1,187 Asia 3,468 2,200 All other countries 3,335 328 Consolidated $ 31,768 $ 21,503

Income (Loss) Per Share (Tables

Income (Loss) Per Share (Tables)	3 Months Ended
Income (Loss) Per Share (Tables)	Mar. 31, 2021
Income (Loss) Per Share [Abstract]
Reconciliation Between Basic And Diluted Earnings Per Share	Three Months Ended March 31, 2021 March 31, 2020 Numerator: Net income (loss) $ 672 $ ( 1,979 ) Less: Loss allocated to non-controlling interest ( 42 ) - Net income (loss) attributable to Intricon shareholders $ 714 $ ( 1,979 ) Denominator: Basic – weighted shares outstanding 8,994 8,813 Weighted shares assumed upon exercise of stock awards 613 - Diluted – weighted shares outstanding 9,607 8,813 Basic income (loss) per share attributable to Intricon shareholders: $ 0.08 $ ( 0.22 ) Diluted income (loss) per share attributable to Intricon shareholders: $ 0.07 $ ( 0.22 )

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
Income Taxes (Tables)	Mar. 31, 2021
Income Taxes [Abstract]
Schedule Of Income (Loss) Before Income Taxes	Three Months Ended March 31, 2021 March 31, 2020 United States $ 585 $ ( 1,842 ) Singapore 138 ( 153 ) Indonesia 21 18 Germany 18 16 Income (loss) before income taxes $ 762 $ ( 1,961 )

Business Combination (Tables)

Business Combination (Tables)	3 Months Ended
Business Combination (Tables)	Mar. 31, 2021
Business Combination [Abstract]
Schedule Of Identifiable Assets Acquired And Liabilities Assumed	Current assets $ 3,161 Property, plant and equipment 360 Intangible assets 6,400 Goodwill 4,253 Noncurrent assets 169 Current liabilities ( 1,105 ) Noncurrent liabilities ( 1,423 ) Total consideration paid $ 11,815
Reconciliation Of The Contingent Consideration Liability Measured And Carried At Fair Value On Recurring Basis	Carrying amount at December 31, 2020 $ 3,574 Change in fair value 35 Carrying amount at March 31, 2021 $ 3,609

Selected Balance Sheet Data (Ta

Selected Balance Sheet Data (Tables)	3 Months Ended
Selected Balance Sheet Data (Tables)	Mar. 31, 2021
Selected Balance Sheet Data [Abstract]
Schedule Of Inventories	Raw materials Work-in process Finished products and components Total March 31, 2021 Domestic $ 12,256 $ 1,191 $ 2,138 $ 15,585 Foreign 3,396 1,239 116 4,751 Total $ 15,652 $ 2,430 $ 2,254 $ 20,336 December 31, 2020 Domestic $ 11,371 $ 1,499 $ 2,149 $ 15,019 Foreign 3,393 968 133 4,494 Total $ 14,764 $ 2,467 $ 2,282 $ 19,513
Geographical Distribution Of Long-Lived Assets, Net	March 31, December 31, 2021 2020 United States $ 12,537 $ 12,539 Singapore 1,454 1,460 Other 170 178 Consolidated $ 14,161 $ 14,177
Schedule Of Goodwill	Carrying amount at December 31, 2020 $ 13,714 Purchase accounting adjustment 90 Carrying amount at March 31, 2021 $ 13,804
Summary Of Intangible Assets	March 31, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer list $ 6,400 $ ( 667 ) $ 5,733 Technology intangibles 6,725 ( 2,170 ) 4,555 Total $ 13,125 $ ( 2,837 ) $ 10,288 December 31, 2020 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer list $ 6,400 $ ( 467 ) $ 5,933 Technology intangibles 6,725 ( 1,873 ) 4,852 Total $ 13,125 $ ( 2,340 ) $ 10,785
Investments in Partnerships	March 31, December 31, 2021 2020 Investment in Signison $ 358 $ 418 Other 242 152 Total $ 600 $ 570
Components Of Other Accrued Liabilities	March 31, 2021 December 31, 2020 Pension and postretirement benefit obligations $ 188 $ 188 Deferred revenue 224 184 Current technology intangible liability 996 1,006 Current earn-out contingent consideration liability 1,060 1,090 Customer funded projects 776 759 Other 1,053 1,008 Total $ 4,297 $ 4,235
Schedule Of Other Long-Term Liabilities	March 31, December 31, 2021 2020 Noncurrent technology intangible liability $ 710 $ 1,039 Noncurrent earn-out contingent consideration liability 2,549 2,484 Other 880 875 Total $ 4,139 $ 4,398

Investment Securities (Tables)

Investment Securities (Tables)	3 Months Ended
Investment Securities (Tables)	Mar. 31, 2021
Investment Securities [Abstract]
Summary Of Maturity Dates Of Investments	The maturity dates of our investments as of March 31, 2020 are as follows: Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 10,140 $ - $ 10,140 Corporate Notes and Bonds 13,559 2,765 16,324 Total Investments $ 23,699 $ 2,765 $ 26,464 The maturity dates of our investments as of December 31, 2020 are as follows: Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 7,490 $ - $ 7,490 Corporate Notes and Bonds 12,303 5,085 17,388 Total Investments $ 19,793 $ 5,085 $ 24,878

Leases (Tables)

Leases (Tables)	3 Months Ended
Leases (Tables)	Mar. 31, 2021
Leases [Abstract]
Summary Of Weighted-Average Lease Term And Discount Rate	Weighted-Average Lease Term (Years) March 31, 2021 December 31, 2020 Finance leases 0.8 0.8 Operating leases 3.6 3.8 Weighted-Average Discount Rate March 31, 2021 December 31, 2020 Finance leases 5.56 % 5.56 % Operating leases 5.06 % 5.06 %
Summary Of Lease Costs By Type	March 31, 2021 March 31, 2020 Lease cost Finance lease cost: Amortization of right-of-use assets $ 10 $ 26 Interest on lease liabilities 1 2 Operating lease cost 582 481 Variable lease cost 120 151 Total lease cost $ 713 $ 660
Maturities Of Lease Liabilities	Operating Leases Financing Leases Total 2021 $ 2,108 $ 12 $ 2,120 2022 1,938 3 1,941 2023 1,338 - 1,338 2024 1,017 - 1,017 2025 and thereafter 471 - 471 Total lease payments 6,872 15 6,887 Less: Interest ( 598 ) ( 3 ) ( 601 ) Present value of lease liabilities $ 6,274 $ 12 6,286

Shareholders' Equity And Stoc_2

Shareholders' Equity And Stock-Based Compensation (Tables)	3 Months Ended
Shareholders' Equity And Stock-Based Compensation (Tables)	Mar. 31, 2021
Shareholders' Equity And Stock-Based Compensation [Abstract]
Summary Of Stock Option Activity	Outstanding Awards Stock Options RSUs Total Stock Option Weighted-Average Exercise Price (a) Aggregate Intrinsic Value Outstanding at December 31, 2020 690 217 907 $ 6.51 Awards granted - 73 73 - Awards exercised or released ( 31 ) ( 53 ) ( 84 ) 5.26 Outstanding at March 31, 2021 659 237 896 $ 6.57 $ 19,045 Exercisable at March 31, 2021 659 659 $ 6.57 $ 12,572 Available for future grant at December 31, 2020 73 Available for future grant at March 31, 2021 (b) 20 (a) The weighted average exercise price calculation does not include outstanding RSUs (b) Does not include an additional 500 shares approved by shareholders on May 4, 2021

Management's Statement (Narrati

Management's Statement (Narrative) (Details)	3 Months Ended
Management's Statement (Narrative) (Details)	Mar. 31, 2021segment
Management's Statement [Abstract]
Number of operating segments	1

Revenue Recognition (Narrative)

Revenue Recognition (Narrative) (Details) $ in Thousands	3 Months Ended		12 Months Ended
Revenue Recognition (Narrative) (Details) $ in Thousands	Mar. 31, 2021USD ($)customer	Mar. 31, 2020USD ($)customer	Dec. 31, 2020customer
Disaggregation of Revenue [Line Items]
Total Net Revenue	$ 31,768	$ 21,503
Cost of goods sold	$ 23,558	16,931
Other Medical Market Error Correction [Member] \| Cumulative Effect, Period of Adoption, Adjustment [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenue		(1,200,000)
Cost of goods sold		$ (800,000)
One Customer [Member] \| Net Revenue [Member] \| Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of risk	68.00%	63.00%
Number of customers \| customer	1	1
Two Customers [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of risk	60.00%		69.00%
Number of customers \| customer	2		2
Two Customers [Member] \| Contract Assets [Member] \| Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Number of customers \| customer	2		2

Revenue Recognition (Timing Of

Revenue Recognition (Timing Of Revenue Recognition) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue, Major Customer [Line Items]
Total Net Revenue	$ 31,768	$ 21,503
Products And Services Transferred At Point In Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	12,036	6,965
Products And Services Transferred Over Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	19,732	14,538
Diabetes [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	18,364	13,530
Diabetes [Member] \| Products And Services Transferred Over Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	18,364	13,530
Interventional Catheters [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	3,802
Interventional Catheters [Member] \| Products And Services Transferred At Point In Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	3,802
Other Medical [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	2,958	2,828
Other Medical [Member] \| Products And Services Transferred At Point In Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,590	1,820
Other Medical [Member] \| Products And Services Transferred Over Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,368	1,008
Value Based DTEC [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	937	1,173
Value Based DTEC [Member] \| Products And Services Transferred At Point In Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	937	1,173
Value Based ITEC [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,301	744
Value Based ITEC [Member] \| Products And Services Transferred At Point In Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	1,301	744
Legacy OEM [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	3,421	1,964
Legacy OEM [Member] \| Products And Services Transferred At Point In Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	3,421	1,964
Professional Audio Communications [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	985	1,264
Professional Audio Communications [Member] \| Products And Services Transferred At Point In Time [Member]
Revenue, Major Customer [Line Items]
Total Net Revenue	$ 985	$ 1,264

Revenue Recognition (Net Revenu

Revenue Recognition (Net Revenue by Geography) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	$ 31,768	$ 21,503
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	23,701	17,788
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	1,264	1,187
Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	3,468	2,200
All Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue, net	$ 3,335	$ 328

Income (Loss) Per Share (Narrat

Income (Loss) Per Share (Narrative) (Details) - shares	3 Months Ended
Income (Loss) Per Share (Narrative) (Details) - shares	Mar. 31, 2021	Mar. 31, 2020
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from computation of diluted income per share	0	893,000

Income (Loss) Per Share (Reconc

Income (Loss) Per Share (Reconciliation Between Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income (Loss) Per Share [Abstract]
Net income (loss)	$ 672	$ (1,979)
Less: Loss allocated to non-controlling interest	(42)
Net income (loss) attributable to Intricon shareholders	$ 714	$ (1,979)
Basic - weighted shares outstanding	8,994	8,813
Weighted shares assumed upon exercise of stock awards	613
Diluted - weighted shares outstanding	9,607	8,813
Basic income (loss) per share attributable to Intricon shareholders:	$ 0.08	$ (0.22)
Net income per share, Diluted:	$ 0.07	$ (0.22)

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Income Taxes [Abstract]
Income tax expense	$ 90	$ 18

Income Taxes (Schedule Of Incom

Income Taxes (Schedule Of Income (Loss) Before Income Taxes) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes	$ 762	$ (1,961)
United States IRS [Member]
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes	585	(1,842)
Singapore Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes	138	(153)
Indonesia Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes	21	18
Federal Ministry Of Finance Germany [Member]
Operating Loss Carryforwards [Line Items]
Income (loss) before income taxes	$ 18	$ 16

Business Combination (Narrative

Business Combination (Narrative) (Details) - USD ($) $ in Thousands	May 18, 2020	Mar. 31, 2021
Business Acquisition [Line Items]
Purchase accounting adjustments, increase in goodwill		$ 90
Revenue		3,802
Net income		$ 249
Emerald Medical Services Pte., Ltd [Member] \| Emerald Extrusion Services LLC [Member]
Business Acquisition [Line Items]
Equity method, ownership interest	54.00%
Emerald Medical Services Pte., Ltd [Member]
Business Acquisition [Line Items]
Acquisition date		May 18, 2020
Purchase price	$ 11,815

Business Combination (Schedule

Business Combination (Schedule Of Identifiable Assets Acquired And Liabilities Assumed) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 13,804	$ 13,714
Emerald Medical Services And Emerald Extrusion Services [Member]
Business Acquisition [Line Items]
Current assets	3,161
Property, plant and equipment	360
Intangible assets	6,400
Goodwill	4,253
Noncurrent assets	169
Current liabilities	(1,105)
Noncurrent liabilities	(1,423)
Total consideration paid	$ 11,815

Business Combination (Reconcili

Business Combination (Reconciliation Of The Contingent Consideration Liability Measured And Carried At Fair Value On Recurring Basis) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Business Combination [Abstract]
Carrying amount at December 31, 2020	$ 3,574
Change in fair value	35
Carrying amount at March 31, 2021	$ 3,609

Selected Balance Sheet Data (Na

Selected Balance Sheet Data (Narrative) (Details)	3 Months Ended
Selected Balance Sheet Data (Narrative) (Details)	Mar. 31, 2021USD ($)
Finite-Lived Intangible Assets [Line Items]
Credit facility, outstanding balance	$ 0
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	8 years
Minimum [Member] \| Technology Intangibles [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	5 years
Maximum [Member] \| Technology Intangibles [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	7 years
Signison [Member]
Finite-Lived Intangible Assets [Line Items]
Equity method, ownership interest	50.00%

Selected Balance Sheet Data (Sc

Selected Balance Sheet Data (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory [Line Items]
Raw materials	$ 15,652	$ 14,764
Work-in process	2,430	2,467
Finished products and components	2,254	2,282
Total	20,336	19,513
Domestic [Member]
Inventory [Line Items]
Raw materials	12,256	11,371
Work-in process	1,191	1,499
Finished products and components	2,138	2,149
Total	15,585	15,019
Foreign [Member]
Inventory [Line Items]
Raw materials	3,396	3,393
Work-in process	1,239	968
Finished products and components	116	133
Total	$ 4,751	$ 4,494

Selected Balance Sheet Data (Ge

Selected Balance Sheet Data (Geographical Distribution Of Long-Lived Assets, Net) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	$ 14,161	$ 14,177
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	12,537	12,539
Singapore [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	1,454	1,460
Other Geographical [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Consolidated	$ 170	$ 178

Selected Balance Sheet Data (_2

Selected Balance Sheet Data (Schedule Of Goodwill) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Intangible Assets [Abstract]
Carrying amount, Beginning Balance	$ 13,714
Purchase accounting adjustment	90
Carrying amount, Ending Balance	$ 13,804

Selected Balance Sheet Data (Su

Selected Balance Sheet Data (Summary Of Intangible Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 13,125	$ 13,125
Accumulated Amortization	(2,837)	(2,340)
Net Carrying Amount	10,288	10,785
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,400	6,400
Accumulated Amortization	(667)	(467)
Net Carrying Amount	5,733	5,933
Technology Intangibles [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,725	6,725
Accumulated Amortization	(2,170)	(1,873)
Net Carrying Amount	$ 4,555	$ 4,852

Selected Balance Sheet Data (In

Selected Balance Sheet Data (Investments in Partnerships) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Total	$ 600	$ 570
Signison [Member]
Schedule of Equity Method Investments [Line Items]
Total	358	418
Other Investment [Member]
Schedule of Equity Method Investments [Line Items]
Total	$ 242	$ 152

Selected Balance Sheet Data (Co

Selected Balance Sheet Data (Components Of Other Accrued Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Other Accrued Liabilities [Abstract]
Pension and postretirement benefit obligations	$ 188	$ 188
Deferred revenue	224	184
Current technology intangible liability	996	1,006
Current earn-out contingent consideration liability	1,060	1,090
Customer funded projects	776	759
Other	1,053	1,008
Total	$ 4,297	$ 4,235

Selected Balance Sheet Data (_3

Selected Balance Sheet Data (Schedule Of Other Long-Term Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Other Long-Term Liabilities [Abstract]
Noncurrent technology intangible liability	$ 710	$ 1,039
Noncurrent earn-out contingent consideration liability	2,549	2,484
Other	880	875
Total	$ 4,139	$ 4,398

Investment Securities (Narrativ

Investment Securities (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Cash	$ 6,181	$ 6,697
Maximum [Member]
Cash and Cash Equivalents [Line Items]
Maturities benchmark for determining investment in commercial paper, corporate notes and bonds	2 years

Investment Securities (Summary

Investment Securities (Summary Of Maturity Dates Of Investments) (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Less than one year	$ 23,699	$ 19,793
1-5 years	2,765	5,085
Total	26,464	24,878
Commercial Paper Original Maturities of 91 Days or More [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Less than one year	10,140	7,490
Total	10,140	7,490
Corporate Notes And Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Less than one year	13,559	12,303
1-5 years	2,765	5,085
Total	$ 16,324	$ 17,388

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Thousands	3 Months Ended
Leases (Narrative) (Details) $ in Thousands	Mar. 31, 2021USD ($)item	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
Lessee, Lease, Description [Line Items]
Incremental borrowing rates terms, discount rates	5 years
Operating Lease, Payments \| $	$ 609	$ 507
ROU asset \| $	6,115		$ 6,701
Lease liability \| $	$ 6,274
Minnesota [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	3
California [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
Illinois [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
Singapore [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
Indonesia [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
ROU asset \| $	$ 103
Lease liability \| $	$ 72
Germany [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
Lease Expiration In 2022 [Member] \| Minnesota [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	2
Lease Expiration In 2023 [Member] \| Minnesota [Member]
Lessee, Lease, Description [Line Items]
Number of leased facilities	1
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Lessee, Operating Lease, Renewal Term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Renewal Term	5 years

Leases (Summary Of Weighted-Ave

Leases (Summary Of Weighted-Average Lease Term And Discount Rate) (Details)	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Finance leases, Weighted Average Lease Term	9 months 18 days	9 months 18 days
Operating leases, Weighted Average Lease Term	3 years 7 months 6 days	3 years 9 months 18 days
Finance leases, Weighted Average Discount Rate	5.56%	5.56%
Operating leases, Weighted Average Discount Rate	5.06%	5.06%

Leases (Summary Of Lease Costs

Leases (Summary Of Lease Costs By Type) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Amortization of right-of-use assets	$ 10	$ 26
Interest on lease liabilities	1	2
Operating lease cost	582	481
Variable lease cost	120	151
Total lease cost	$ 713	$ 660

Leases (Maturities Of Lease Lia

Leases (Maturities Of Lease Liabilities) (Details) $ in Thousands	Mar. 31, 2021USD ($)
Leases [Abstract]
Operating Leases, 2021	$ 2,108
Operating Leases, 2022	1,938
Operating Leases, 2023	1,338
Operating Leases, 2024	1,017
Operating Leases, 2025 and thereafter	471
Operating Leases, Total lease payments	6,872
Operating Leases, Less: Interest	(598)
Operating Leases, Present value of lease liabilities	6,274
Financing Leases, 2021	12
Financing Leases, 2022	3
Financing Leases, Total lease payments	15
Financing Leases, Less: Interest	(3)
Financing Leases, Present value of lease liabilities	12
Lease, Liability, 2021	2,120
Lease, Liability, 2022	1,941
Lease, Liability, 2023	1,338
Lease, Liability, 2024	1,017
Lease, Liability, 2025 and thereafter	471
Lease, Liability, Total lease payments	6,887
Lease, Less: Interest	(601)
Lease, Present value of lease liabilities	$ 6,286

Shareholders' Equity And Stoc_3

Shareholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	May 04, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock for which awards can be granted		20,000		73,000
Number of Shares, Awards granted		73,000
Shares purchased for award		2,000	5,000
Stock compensation expense		$ 453	$ 376
Unrecognized compensation costs related to non-vested awards		$ 3,012
Unrecognized compensation costs related to non-vested awards, recognition period		2 years 3 months 29 days
Total intrinsic value of options exercised		$ 486
Maximum number of shares approved under purchase plan		300,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Number of Shares, Awards granted		0
Forfeitures in order to cover exercise price		7,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Number of Shares, Awards granted		73,000
Weighted average fair value of units granted		$ 20.80
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in maximum number of shares approved	500,000
Maximum [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of options		10 years
Maximum [Member] \| 2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock for which awards can be granted		297,000

Shareholders' Equity And Stoc_4

Shareholders' Equity And Stock-Based Compensation (Summary Of Stock Option Activity) (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	907,000
Number of Shares, Awards granted	73,000
Number of Shares, Awards exercised or released	(84,000)
Number of Shares, Outstanding	896,000
Number of Shares, Exercisable	659,000
Number of Shares, Available for future grant at beginning of period	73,000
Number of Shares, Available for future grant at end of period	20,000
Weighted-average Exercise Price, Outstanding \| $ / shares	$ 6.51
Weighted-average Exercise Price, Awards exercised or released \| $ / shares	5.26
Weighted-average Exercise Price, Outstanding \| $ / shares	6.57
Weighted-average Exercise Price, Exercisable \| $ / shares	$ 6.57
Aggregate Intrinsic Value, Outstanding \| $	$ 19,045
Aggregate Intrinsic Value, Exercisable \| $	$ 12,572
Additional number of shares authorized	500,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	690,000
Number of Shares, Awards granted	0
Number of Shares, Awards exercised or released	(31,000)
Number of Shares, Outstanding	659,000
Number of Shares, Exercisable	659,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	217,000
Number of Shares, Awards granted	73,000
Number of Shares, Awards exercised or released	(53,000)
Number of Shares, Outstanding	237,000

Legal Proceedings (Narrative) (

Legal Proceedings (Narrative) (Details) $ in Thousands	3 Months Ended
Legal Proceedings (Narrative) (Details) $ in Thousands	Mar. 31, 2021USD ($)item
Other Accrued Liabilities [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Estimated future claims	$ 129
Other Long Term Liabilities [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Estimated future claims	721
Other Current Assets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Insurance receivable	129
Other Assets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Insurance receivable	$ 721
Maximum [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Potential exposure, per call \| item	1,500
Minimum [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Potential exposure, per call \| item	500